1-(oxetan-3-yl)-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazine | 1430472-63-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-(oxetan-3-yl)-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazine
• 英文别名: 1-(oxetan-3-yl)-4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperazine
• CAS: 1430472-63-1
• 化学式: C₁₉H₂₉BN₂O₃
• 分子量: 344.262
• InChiKey: FSGAFXDIYMOISL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.51
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.68
• 拓扑面积：
  34.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  7-(苯磺酰基)-4-氯-6-碘-7H-吡咯并[2,3-d]嘧啶 、 1-(oxetan-3-yl)-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazine 在 四(三苯基膦)钯 、 sodium carbonate 作用下， 以 乙二醇二甲醚 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.5h， 生成 5-(6-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-2-((tetrahydro-2H-pyran-4-yl)oxy)benzonitrile
  参考文献：
  名称：

  [EN] TANK-BINDING KINASE INHIBITOR COMPOUNDS
  [FR] COMPOSÉS INHIBITEURS DE KINASES SE LIANT À TANK

  摘要：

  揭示了具有以下化学式（I）的化合物及其使用和制备方法。

  公开号：

  WO2015187684A1
• 作为产物：
  描述：

  1-(4-溴苯基)哌嗪 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 potassium acetate 、 三乙酰氧基硼氢化钠 、 溶剂黄146 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 3.0h， 生成 1-(oxetan-3-yl)-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazine
  参考文献：
  名称：

  [EN] FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS
  [FR] COMPOSÉS HÉTÉROCYCLIQUES CONDENSÉS UTILISÉS EN TANT QU'INHIBITEURS DE PI3KALPHA

  摘要：

  The present disclosure describes antagonists of the enzyme. The present disclosure provides compounds having a structure set forth in Formula (VI), (VII), (VII-1) or (VIII), the stereoisomer or pharmaceutically acceptable salts, solvates and prodrugs thereof. Further provided are uses of the compounds of Formula (VI), (VII), (VII-1) or (VIII) in treating cancers.

  公开号：

  WO2023104111A1

文献信息

• Syk 억제제
  申请人：GILEAD SCIENCES, INC. 길리애드 사이언시즈, 인코포레이티드(519990290219)

  公开号：KR20160037198A

  公开（公告）日：2016-04-05

  본 개시내용은 Syk 억제제인 화합물, 및 암 및 염증성 상태를 비롯한 다양한 질환 상태의 치료에서의 그의 용도에 관한 것이다. 특정한 실시양태에서, 화합물의 구조는 하기 화학식 I로 주어진다. 003c#화학식 I003e# 상기 식에서, X, X, X, R, R, R, R, 및 Y는 본원에 기재된 바와 같다. 본 개시내용은 화학식 I의 화합물 또는 그의 제약상 허용되는 염을 포함하는 제약 조성물, 및 Syk에 의해 매개되는 상태를 치료하기 위해 이들 화합물 및 조성물을 사용하는 방법을 추가로 제공한다.

  This text appears to be a scientific or technical document discussing the therapeutic uses of a compound called Syk inhibitor in the treatment of various conditions including cancer and inflammatory diseases. It also mentions the chemical structure of the compound given by the chemical formula I. In the formula, X, X, X, R, R, R, R, and Y are as described in the specification. The document further provides methods for using these compounds and compositions containing compounds or salts thereof of the chemical formula I to treat conditions mediated by Syk.
• SYK INHIBITORS
  申请人：Gilead Sciences, Inc.

  公开号：US20150038488A1

  公开（公告）日：2015-02-05

  The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I wherein X 1 , X 2 , X 3 , R 2 , R 3 , R 4 , R 5 , and Y are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.

  本公开涉及的化合物是Syk抑制剂，并且适用于治疗各种疾病状态，包括癌症和炎症性疾病。在特定实施例中，化合物的结构由公式I给出，其中X1、X2、X3、R2、R3、R4、R5和Y如本文所述。本公开进一步提供了包括公式I的化合物或其药学上可接受的盐的制药组合物，以及使用这些化合物和组合物治疗Syk介导的疾病的方法。
• TANK-BINDING KINASE INHIBITOR COMPOUNDS
  申请人：Du Zhimin

  公开号：US20150344473A1

  公开（公告）日：2015-12-03

  Compounds having the following formula (I) and methods of their use and preparation are disclosed:

  公开具有以下式（I）的化合物及其使用和制备方法：
• Substituted pyrrolidines as SYK inhibitors
  申请人：Gilead Sciences, Inc.

  公开号：US09376441B2

  公开（公告）日：2016-06-28

  The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: wherein X1, X2, X3, R2, R3, R4, R5, and Y are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.

  本公开涉及的化合物是Syk抑制剂，用于治疗各种疾病状态，包括癌症和炎症疾病。在特定实施例中，化合物的结构由公式I给出：其中X1、X2、X3、R2、R3、R4、R5和Y如本文所述。本公开还提供了含有公式I的化合物或其药学上可接受的盐的药物组合物，以及使用这些化合物和组合物治疗由Syk介导的疾病状态的方法。
• [EN] SUBSTITUTED PYRAZOLO PIPERIDINE CARBOXYLIC ACIDS<br/>[FR] ACIDES PYRAZOLO PIPÉRIDINE CARBOXYLIQUES SUBSTITUÉS
  申请人：BAYER AG

  公开号：WO2022122913A1

  公开（公告）日：2022-06-16

  The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).

  本发明涉及取代的吡唑啉哌啶羧酸及其盐的制备方法，以及它们用于制备治疗和/或预防疾病的药物，特别是心血管和心脏疾病，优选为收缩功能减弱和保留的心衰（HFrEF，HFmrEF和HFpEF），高血压（HTN），周围动脉疾病（PAD，PAOD），心肾和肾脏疾病，优选为慢性和糖尿病肾病（CKD和DKD），心肺和肺部疾病，优选为肺动脉高压（PH），以及其他疾病，优选为神经退行性疾病和不同形式的痴呆症，纤维性疾病，系统性硬化症（SSc），镰状细胞病（SCD），创面愈合障碍，如糖尿病足溃疡（DFU）。